Skip to main content

Advertisement

SpringerLink
Log in

Psychiatric aspects of Parkinson’s disease

An Update

  • REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract.

In patients with Parkinson’s disease (PD) disturbances of mental state constitute some of the most difficult treatment challenges of advanced disease, often limiting effective treatment of motor symptoms and leading to increased disability and poor quality of life. This article provides an update on the current knowledge of these complications and the use of old and new drugs in their management. Mental state alterations in PD include depression, anxiety, cognitive impairment, apathy, and treatment-related psychiatric symptoms. The latter range from vivid dreams and hallucinations to delusions, manic symptoms, hypersexuality, dopamine dysregulation syndrome and delirium. While some of these symptoms may be alleviated by anti-parkinsonian medication, especially if they are off-period related, treatment-related phenomena are usually exacerbated by increasing the number or dosage of antiparkinsonian drugs. Elimination of exacerbating factors and simplification of drug regimes are the first and most important steps in improvement of such symptoms. However, the advent of atypical antipsychotics such as clozapine has dramatically helped the management of treatment-related psychiatric complications in PD. In patients with dementia associated with PD cognitive functioning and behavioural problems appear to respond to cholinesterase inhibitors, such as rivastigmine or donepezil. Depression is a common problem in early as well as advanced PD, and selective serotonin reuptake inhibitors, reboxetine, and tricyclic antidepressants have been reported to be effective and well tolerated antidepressants. Randomised, controlled studies are required to assess the differential efficacy and tolerability of antidepressants in patients with PD, including the newer antidepressants with serotonergic and noradrenergic properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:492–496

    CAS  PubMed  Google Scholar 

  2. Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601

    Article  CAS  PubMed  Google Scholar 

  3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48:938–942

    CAS  PubMed  Google Scholar 

  4. Aarsland D, Cummings JL, Larsen JP (2001) Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 16:184–191

    Article  CAS  PubMed  Google Scholar 

  5. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 16:528–536

    Article  CAS  PubMed  Google Scholar 

  6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392

    Article  PubMed  Google Scholar 

  7. Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:42–49

    Article  CAS  PubMed  Google Scholar 

  8. Barrett K (1991) Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry 54:718–721

    CAS  PubMed  Google Scholar 

  9. Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 25:107–110

    Article  CAS  PubMed  Google Scholar 

  10. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 18:258–264

    Article  CAS  PubMed  Google Scholar 

  11. Ceravolo R, Nuti A, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, Dell’Osso L, Murri L, Bonuccelli U (2000) Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 55:1216–1218

    CAS  PubMed  Google Scholar 

  12. Chatterjee A, Fahn S (2002) Methylphenidate treats apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 14:461–462

    Article  PubMed  Google Scholar 

  13. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714

    CAS  PubMed  Google Scholar 

  14. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58–65

    Article  CAS  PubMed  Google Scholar 

  15. Cubo E, Bernard B, Leurgans S, Raman R (2000) Cognitive and motor function in patients with Parkinson’s disease with and without depression. Clin Neuropharmacol 23:331–334

    Article  CAS  PubMed  Google Scholar 

  16. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002) Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia 40:2257–2267

    Article  CAS  PubMed  Google Scholar 

  17. Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227

    Article  CAS  PubMed  Google Scholar 

  18. Deuschl G, Wenzelburger R, Kopper F, Volkmann J (2003) Deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: a therapy approaching evidence-based standards. J Neurol 250(Suppl 1):I43–I46

    Article  PubMed  Google Scholar 

  19. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2000) Brain serotonin IA receptors in Parkinson’s disease with and without depression measured by positron emission tomography with 11C-WAY 10635. Mov Disord 15:213

    Google Scholar 

  20. de Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45:1161–1164

    CAS  PubMed  Google Scholar 

  21. Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS (2002) Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study. Mov Disord 17:528–532

    Article  PubMed  Google Scholar 

  22. Ellgring H, Seiler S, Perleth B, Frings W, Gasser T, Oertel W (1993) Psychosocial aspects of Parkinson’s disease. Neurology 43(12 Suppl 6):S41–S44

    CAS  PubMed  Google Scholar 

  23. Emre M (2003) What causes mental dysfunction in Parkinson’s disease? Mov Disord 18(Suppl 6):S63–S71

    Article  Google Scholar 

  24. Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745

    Article  PubMed  Google Scholar 

  25. Friedman JH, Feinberg SS, Feldman RG (1985) A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 254:2792–2795

    Article  CAS  PubMed  Google Scholar 

  26. Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, Simon ES, Korczyn AD (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm 107:59–71

    Article  CAS  PubMed  Google Scholar 

  27. Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428

    Article  CAS  PubMed  Google Scholar 

  28. Global Parkinson’s Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17:60–67

    Article  PubMed  Google Scholar 

  29. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794

    CAS  PubMed  Google Scholar 

  30. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57:2078–2082

    CAS  PubMed  Google Scholar 

  31. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671

    CAS  PubMed  Google Scholar 

  32. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53:1284–1291

    CAS  PubMed  Google Scholar 

  33. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49:381–389

    CAS  PubMed  Google Scholar 

  34. Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G (1994) Depression in Parkinson’s disease. Am J Psychiatry 151:1010–1014

    CAS  PubMed  Google Scholar 

  35. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102:355–363

    CAS  Google Scholar 

  36. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, du Moncel ST, Bonnet AM, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 72:701–707

    Article  CAS  PubMed  Google Scholar 

  37. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602

    CAS  PubMed  Google Scholar 

  38. Higginson CI, Fields JA, Troster AI (2001) Which symptoms of anxiety diminish after surgical interventions for Parkinson disease? Neuropsychiatry Neuropsychol Behav Neurol 14:117–121

    CAS  PubMed  Google Scholar 

  39. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:734–738

    Article  CAS  PubMed  Google Scholar 

  40. Huckvale C, Richardson AM, Mann DM, Pickering-Brown SM (2003) Debrisoquine hydroxylase gene polymorphism (CYP2D6*4) in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 74:135–136

    Article  CAS  PubMed  Google Scholar 

  41. Fukuda M, Kameyama S, Yoshino M, Tanaka R, Narabayashi H (2000) Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson’s disease. Stereotact Funct Neurosurg 74:11–20

    Article  CAS  PubMed  Google Scholar 

  42. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921

    CAS  PubMed  Google Scholar 

  43. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 61:324–325

    CAS  Google Scholar 

  44. Inzelberg R, Chapman J, Treves TA, Asherov A, Kipervasser S, Hilkewicz O, Verchovsky R, Klimowitzky S, Korczyn AD (1998) Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 12:45–48

    CAS  PubMed  Google Scholar 

  45. Jellinger KA (2000) Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm 59(Suppl):185–212

    CAS  Google Scholar 

  46. Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:431–435

    CAS  PubMed  Google Scholar 

  47. Korczyn AD (2001) Dementia in Parkinson’s disease. J Neurol 248(Suppl 3):III1–III4

    PubMed  Google Scholar 

  48. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Pares P (2002) Mania following deep brain stimulation for Parkinson’s disease. Neurology 59:1421–1424

    CAS  PubMed  Google Scholar 

  49. Leentjens AF, Lousberg R, Verhey FR (2002) Markers for depression in Parkinson’s disease. Acta Psychiatr Scand 106:196–201

    Article  CAS  PubMed  Google Scholar 

  50. Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106:257–270

    PubMed  Google Scholar 

  51. Lemke MR (2002) Effect of reboxetine on depression in Parkinson’s disease patients. J Clin Psychiatry 63:300–304

    CAS  PubMed  Google Scholar 

  52. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002a) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729

    Article  Google Scholar 

  53. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, Stern Y, Marder K (2002b) The association of incident dementia with mortality in PD. Neurology 59:1708–1713

    CAS  Google Scholar 

  54. Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson disease. Arch Neurol 54:260–264

    CAS  PubMed  Google Scholar 

  55. Manford M, Andermann F (1998) Complex visual hallucinations. Clinical and neurobiological insights. Brain 121:1819–1840

    Article  PubMed  Google Scholar 

  56. Maricle RA, Nutt JG, Valentine RJ, Carter JH (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 45:1757–1760

    CAS  PubMed  Google Scholar 

  57. Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64

    CAS  PubMed  Google Scholar 

  58. Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson disease. Neurology 31:645–650

    CAS  PubMed  Google Scholar 

  59. Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, Cote L, Stern Y (1990) An estimate of the incidence of dementia in idiopathic Parkinson’s disease. Neurology 40:1513–1517

    CAS  PubMed  Google Scholar 

  60. Mayeux R (1992) The mental status in Parkinson’s disease. In: Koller WC (ed). Handbook of Parkinson’s disease. Second edition. Marcel Dekker Inc., pp 159–184

  61. Mayeux R (1990) The “serotonin hypothesis” for depression in Parkinson’s disease. Adv Neurol 53:163–166

    CAS  PubMed  Google Scholar 

  62. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK 2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15:387–392

    Article  CAS  PubMed  Google Scholar 

  63. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124

    CAS  PubMed  Google Scholar 

  64. Melamed E, Friedberg G, Zoldan J (1999) Psychosis: impact on the patient and family. Neurology 52(7 Suppl 3):S14–S16

    CAS  PubMed  Google Scholar 

  65. Merello M, Starkstein S, Nouzeilles MI, Kuzis G, Leiguarda R (2001) Bilateral pallidotomy for treatment of Parkinson’s disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 71:611–614

    Article  CAS  PubMed  Google Scholar 

  66. Moellentine C, Rummans T, Ahlskog JE,Harmsen WS, Suman VJ, O’Connor MK, Black JL, Pileggi T (1998) Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 10:187–193

    CAS  PubMed  Google Scholar 

  67. Moskovitz C, Moses H 3rd, Klawans HL 1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135:669–675

    CAS  PubMed  Google Scholar 

  68. Movement Disorders Task Force (2002) Treatment of depression in idiopathic Parkinson’s disease. Mov Disord 17:112–119

    PubMed  Google Scholar 

  69. Movement Disorders Task Force (2002) Drugs to treat dementia and psychosis. Mov Disord 17:120–127

    Article  Google Scholar 

  70. Naimark D, Jackson E, Rockwell E, Jeste DV (1996) Psychotic symptoms in Parkinson’s disease patients with dementia. J Am Geriatr Soc 44:296–299

    CAS  PubMed  Google Scholar 

  71. Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL (1984) Psychiatric complications of levodopa therapy of Parkinson’s disease. Adv Neurol 40:271–277

    CAS  PubMed  Google Scholar 

  72. Nilsson FM, Kessing LV, Sorensen TM Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211

    Article  PubMed  Google Scholar 

  73. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD (1987) Mood swings associated with the ‘on-off’ phenomenon in Parkinson’s disease. Psychol Med 17:899–904

    CAS  PubMed  Google Scholar 

  74. Oertel WH, Hoglinger GU, Caraceni T, Girotti F, Eichhorn T, Spottke AE, Krieg JC, Poewe W (2001) Depression in Parkinson’s disease. An update. Adv Neurol 86:373–383

    CAS  PubMed  Google Scholar 

  75. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV, et al. (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7:69–67

    CAS  PubMed  Google Scholar 

  76. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin Neuropharmacol 25:21–24

    Article  CAS  PubMed  Google Scholar 

  77. Raudino F (2001) Non motor off in Parkinson’s disease. Acta Neurol Scand 104:312–315

    Article  CAS  PubMed  Google Scholar 

  78. Reading PJ, Luce AK, McKeith IG (2002) Rivastigmine in the treatment of parkinsonian hallucianosis. Neurology 58(Suppl 7):A380

    Google Scholar 

  79. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994) Depression in Parkinson’s disease. A positron emission study. Br J Psychiatry 165:333–339

    CAS  PubMed  Google Scholar 

  80. Romito LM, Raja M, Daniele A, Contarino MF, Bentivoglio AR, Barbier A, Scerrati M, Albanese A (2002) Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord 17:1371–1374

    Article  PubMed  Google Scholar 

  81. Schrag A, Ben-Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249:419–423

    Article  PubMed  Google Scholar 

  82. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69:308–312

    Article  CAS  PubMed  Google Scholar 

  83. Schrag A, Jahanshahi M, Quinn NP (2001) What contributes to depression in Parkinson’s disease? Psychol Med 31:65–73

    Article  CAS  PubMed  Google Scholar 

  84. Scott RB, Harrison J, Boulton C, Wilson J, Gregory R, Parkin S, Bain PG, Joint C, Stein J,Aziz TZ (2002) Global attentional-executive sequelae following surgical lesions to globus pallidus interna. Brain 125:562–574

    Article  PubMed  Google Scholar 

  85. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 15:669–677

    Article  CAS  PubMed  Google Scholar 

  86. Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16:507–510

    Article  CAS  PubMed  Google Scholar 

  87. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139

    CAS  PubMed  Google Scholar 

  88. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson’s disease. J Nerv Ment Dis 178:27–31

    CAS  PubMed  Google Scholar 

  89. Steur EN, Ballering LA (1997) Moclobemide and selegeline in the treatment of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 63:547

    CAS  Google Scholar 

  90. Straits-Troster K, Fields JA, Wilkinson SB, Pahwa R, Lyons KE, Koller WC, Troster AI (2000) Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn 42:399–416

    Article  CAS  PubMed  Google Scholar 

  91. Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 53:175–179

    CAS  PubMed  Google Scholar 

  92. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000) Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 15:986–989

    Article  CAS  PubMed  Google Scholar 

  93. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340:757–763

    Article  PubMed  Google Scholar 

  94. Vijayaraghavan L, Krishnamoorthy ES, Brown RG, Trimble MR (2002) Abulia: a delphi survey of British neurologists and psychiatrists. Mov Disord 17:1052–1057

    Article  PubMed  Google Scholar 

  95. Walsh K, Bennett G (2001) Parkinson’s disease and anxiety. Postgrad Med J 77:89–93

    Article  CAS  PubMed  Google Scholar 

  96. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–413

    PubMed  Google Scholar 

  97. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10–S13

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, UK

    Anette Schrag

Authors
  1. Anette Schrag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anette Schrag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrag, A. Psychiatric aspects of Parkinson’s disease. J Neurol 251, 795–804 (2004). https://doi.org/10.1007/s00415-004-0483-3

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-0483-3

Key words

Search

Navigation